Put yourself through a little pain once per year. You'll be glad you did.
Procedures once again show blazing growth across the globe.
It's not too late to get in on New Relic, a high-flying software-as-a-solution company. Here's why I'm putting my own skin in the game.
While pharmaceutical companies often make it into such lists, the inclusion of a body-cam business and a small e-commerce player may surprise you.
They're both "expensive," but which one has a wider moat?
At first glance, it appears to be a tie. Here's why that's actually not the case.
It's really not a fair fight. Here's why.
Which of these dividend stalwarts is a better fit for your retirement portfolio? The answer may surprise you.
While the pivot to body cameras is important, this platform is what really matters.
Frauds aren't going away. Here are three ways to avoid them.
The infrastructure build-out has created an enormous moat that's not appreciated by the market.
This metric is a popular measuring stick for investors, but there are many other ways to use it.
Everyone wants to see their portfolio go up, so why wouldn't every stock be considered a "growth" stock?
Here's why the stock is up as much as 10% following its earnings release.
The Midwestern convenience store is expecting comps growth of 1.5% to 3% in the current fiscal year.
While the stock is soaring, there are still many headwinds.
In a smartphone world, both of these tech companies should be great buys, right?
In the world of weapons, this titan is the easy winner
Ignore this data point at your own peril.
In a tight battle between two medical device companies, this simple fact is the differentiator.